EpiPen rival Auvi-Q will return to market next year

Mylan Labs' EpiPen price increase has created a public furor of late, and even resulted in a Congressional hearing. Mylan plans to launch a less expensive generic of the EpiPen in the near future, but news today of the impending re-release of Kaleo's Auvi-Q, a competitive auto-injector for treatment of anaphylaxis, has potential to affect Mylan stock. This video from CNBC discusses the competitive outlook.

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.